comprehensive -WSS

comprehensive

author：comprehensive 2025-09-30 22:04:01 - browse：3

Exact Sciences headquarters. -- biotech coverage from STAT — Exact Sciences' headquarters in Madison, Wis. Wikimedia Commons

Exact Sciences reported first-quarter revenues this week that beat market expectations, and the cancer detection company’s executives still believe they’re on track to meet expected 2024 revenue.

That’s usually good news. Yet Exact shares are down nearly 11% on Thursday, dipping to $53.12 within the first few hours of trading. During after-hours trading on Wednesday, shortly after Exact released its financial updates, shares tumbled as low as $47.24.

The seemingly paradoxical result reflects worries about a potential slowdown in future growth at Exact, a $10 billion biotech best known for Cologuard, a colon cancer screening test that detects blood and DNA from stool samples. The test, which first won regulatory approval in 2014, was designed to boost cancer screening rates by providing a more convenient alternative to colonoscopies.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Walensky prepares to leave CDC — and Congress — behind
Next article： Microsoft strikes partnership with Duke Health to advance health AI

WSS

Mega Millions jackpot rises to record $1.55 billion for Tuesday's drawing

15 die by electrocution after transformer explodes in northern India

Nearly two

Who is Magistrate Judge Moxila Upadhyaya in Trump's Jan. 6 case?

BridgeBio heart drug succeeds in pivotal study

ER docs worry over extreme heat as a 'mass casualty event'

hotspot

comprehensive

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Wikipedia

Hepatitis C has a cure — but many Americans still lack access to it

A look at other Americans who have crossed into North Korea over the years

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Dramatically reducing cancer deaths requires the PASTEUR Act

Trump demands the U.S. pay no more for drugs than other countries … again

Verily hires former Apple Health leader as chief scientific officer

Wildfire smoke exposes gaps in outdoor worker protections

Humana, CVS hope to turn members into patients at clinics

Continuity nursing helped my family in our darkest PICU moments

Who is Magistrate Judge Moxila Upadhyaya in Trump's Jan. 6 case?

hotspot

TytoCare raises $49 million to build out AI

Treeline, Josh Bilenker's next biotech, is cloaked in mystery

Attacks on the drug industry will lead to fewer breakthroughs

Microsoft strikes partnership with Duke Health to advance health AI

ProMED, early warning system on disease outbreaks, in peril

Manchin plays down potential 3rd

explore

leisure time

leisure time

hotspot